**Genetic epidemiology of malignant hyperthermia in the United Kingdom**

**Authors**:

DM Miller1,2, C Daly2, EM Aboelsaod1, L Gardner1, SJ Hobson2,3, K Riasat1, S Shepherd3, RL Robinson3, JG Bilmen2, PK Gupta2, M-A Shaw1, PM Hopkins1,2

1. Leeds Institute of Biomedical & Clinical Sciences, University of Leeds, Leeds, UK

2. Malignant Hyperthermia Unit, St James’s University Hospital, Leeds, UK

3. Leeds Genetics Laboratory, St James’s University Hospital, Leeds, UK

**Contribution of authors**

Conception and design of the study: PMH, M-AS

Conduct of experiments and data collection: DMM, CD, LG, SJH, KR, SS, RLR, JGB, PKG, PMH

Data analysis & interpretation: all authors

Drafting of manuscript: PMH

All authors reviewed drafts of the manuscript and approved the final version

**Abbreviated title:** Genetic variants in malignant hyperthermia

**Corresponding author**: Philip M Hopkins, Leeds Institute of Biomedical & Clinical Sciences, St James’s University Hospital, Leeds, LS9 7TF, United Kingdom. Phone +44 113 2065274, Fax +44 113 2064140. Email: p.m.hopkins@leeds.ac.uk

**Disclosure of funding sources:**

National Institutes of Health (NIH): National Institute of Arthritis, Musculoskeletal and Skin Diseases (2P01 AR-05235; P.M.H)

**Abstract**

**Background**:

Gaps in our understanding of genetic susceptibility to malignant hyperthermia limit the application and interpretation of genetic diagnosis of the condition. Our aim was to reduce the knowledge gaps by defining the prevalence and role of variants in the three genes implicated in malignant hyperthermia susceptibility in the largest comprehensively phenotyped malignant hyperthermia cohort worldwide.

**Methods**:

We initially included one individual from each positive family tested in the UK MH Unit since 1971 to detect variants in the *RYR1*, *CACNA1S*, or *STAC3*. Screening for genetic variants has been ongoing since 1991 and has involved a range of techniques, most recently next generation sequencing. We assessed the pathogenicity of variants using standard guidelines, including with family segregation studies. The prevalence of recurrent variants of unknown significance was compared to the prevalence reported in a large database of sequence variants in low risk populations.

**Results**:

We have confirmed malignant hyperthermia susceptibility in 795 independent families, for 722 of which we have a DNA sample. Potentially pathogenic variants were found in 555 families, with 25 *RYR1* and one *CACNA1S* previously unclassified recurrent variants significantly over-represented (*P* < 1 x 10-7) in our cohort compared with the ExAC database. There was genotype-phenotype discordance in 86 of 328 families suitable for segregation analysis. We estimate non-*RYR1/CACNA1S/STAC3* susceptibility occurs in 14-23% of malignant hyperthermia families.

**Conclusions:**

Our data provide the best estimates to date of the role of variants in *RYR1*, *CACNA1S* and *STAC3* in susceptibility to malignant hyperthermia.

**Keywords**

Malignant hyperthermia; genetics, diagnosis: *RYR1:CACNA1S: STAC3*

Malignant hyperthermia (MH) is a potentially fatal reaction that occurs in genetically susceptible individuals exposed to inhalation anaesthetics or succinylcholine1. There has been considerable progress in elucidating the genetic basis of MH susceptibility over the past 30 years2. The *RYR1* gene that encodes the skeletal muscle sarcoplasmic reticulum calcium release channel was the first gene linked to MH susceptibility3, 4 and is involved in 34-86% of cases reported5-12. *RYR1* is a large gene and many variants have been associated with MH susceptibility although only a minority of these have been demonstrated to be pathogenic2. The second gene with variants pathogenic for MH susceptibility is *CACNA1S13, 14*, which encodes the main subunit of the skeletal muscle T-tubule voltage sensor. *STAC3* encodes a protein involved in trafficking the voltage sensor into the correct T-tubular location and subsequently a direct role in excitation-contraction coupling15, 16: homozygous inheritance of the *STAC3* variant p.Trp284Ser leads to a congenital myopathy associated with MH susceptibility17. Such findings have enabled limited application of genetic diagnoses18 but further expansion has been constrained by the difficulty in establishing a pathogenic role for rare missense variants19 and evidence that a simple genetic model may not apply in at least a significant minority of cases20. Our aim in this paper was to define the prevalence of individual variants in *RYR1*, *CACNA1S* and *STAC3* in the largest cohort of phenotypically characterized MH susceptible individuals to date and to assess their likely pathogenicity. We also present data on the proportion of families where there is evidence for more than one genetic variant contributing to MH susceptibility and the proportion where variants in *RYR1*, *CACNA1S* and *STAC3* have been excluded.

**Methods**

**Patients**

We included index cases or, where the index case could not be tested, their nearest relative from families where MH susceptibility had been confirmed following a clinical reaction suggestive of MH. We excluded cases referred where there had been no adverse anaesthetic event, such as those patients referred with a history of exertional heat illness, exertional or recurrent rhabdomyolysis, or a congenital myopathy. MH susceptibility was confirmed by *in vitro* contracture testing (IVCT) or finding of a functionally characterized genetic variant pathogenic for MH susceptibility. The criteria used for diagnosis of MH susceptibility were those of the European MH Group applicable at the time of diagnosis21, 22, 18. Patients tested prior to 1984 were considered susceptible if they developed a contracture of 0.2 g or more upon exposure to 2% halothane. DNA samples were collected, stored and processed according to protocols approved by Leeds (East) Research Ethics Committee or its predecessors: Leeds Teaching Hospitals NHS Trust Clinical Research (Ethics) Committee (East) and Leeds Health Authority / St James’s and Seacroft University Hospitals Clinical Research (Ethics) Committee. All patients contributing DNA samples gave written informed consent.

**Detection of Genetic variants**

This was as described in Merritt and colleagues19. In brief, we began screening MH susceptible families for *RYR1* variants following publication of the first *RYR1* variant implicated in MH susceptibility 23. As further *RYR1* variants were reported we undertook a systematic search for all published variants principally using amplification refractory mutation system or restriction digest assays. As technology developed we used Sanger sequencing of mutation “hot-spots” and then the whole coding region of *RYR1* and *CACNA1S* 5. Most recently, next generation sequencing (NGS) technology has been used24 to sequence the coding sequences of *RYR1, CACNA1S and STAC3*. We defined a potentially pathogenic variant as one with a minor allele frequency (MAF) < 0.001. This is the highest prevalence value that we consider compatible for a single gene disorder with the clinical incidence and penetrance of MH.

**Family studies**

When potentially pathogenic variants are identified in a family, a segregation study of the variant is undertaken for those individuals who have been phenotyped by the IVCT. Again, depending on when the study was done and the nature of the variant this was either using an amplification refractory mutation system test, a restriction digest assay or direct sequencing. When we encountered a case of discordance between familial variant and the IVCT, we reviewed the IVCT records (phenotype) and calculated the probability that the IVCT responses represented an abnormal response 25. We also verified the genotype using Sanger sequencing where a DNA sample was available and, again when feasible, used deep resequencing of *RYR1* and *CACNA1S* to look for alternative disease-associated variants in cases of affected non-carriers.

**Variant prevalence in MH families and the general population**

We defined the prevalence in the UK MH population as the number of independent families carrying a variant divided by the number of independent MH families in whom genetic analyses has been undertaken. For an estimate of the population prevalence of each variant we used data presented in the ExAC browser (http://exac.broadinstitute.org) for the European non-Finnish cohort, unless stated otherwise.

**Predicted pathogenicity of variants**

For each variant we obtained the C-score from website xxxxx. The C-score is derived from Combined Annotation–Dependent Depletion (CADD) and scores of >15 include the 5% predicted most deleterious substitutions in the human genome26.

**Statistical analyses**

We compared the prevalence estimates for potentially pathogenic variants in MH families versus the ExAC cohort using a chi-square test (MedCalc® statistical software [https://www.medcalc.org/calc/comparison\_of\_proportions.php)](https://www.medcalc.org/calc/comparison_of_proportions.php%29). We then used an on-line package (<http://www.danielsoper.com/statcalc/calculator.aspx?id=11)> that enables calculation of exact *P* values up to chi-squared values of 34 (*P* = 1 x 10-8). As we had selected our genes of interest in a non-random way from ~ 20,000 genes in the genome and because we made comparisons for multiple variants we used a *P* value < 1 x 10-7 to infer statistical significance.

**Results**

A total of 770 independent families with MH confirmed by a positive IVCT following a clinical episode consistent with MH susceptibility were identified. DNA samples were available from at least one member of 697 families. Pathogenic *RYR1* variants have been identified by NGS in the probands of a further 25 families since the introduction of NGS as a primary diagnostic test18.

**Variants in the *RYR1* gene**

One hundred and forty-seven different potentially pathogenic variants were found in at least one independent MH family and these are listed in supplementary table 1. Of these, 31 have been previously sufficiently characterized to be used in prospective diagnosis ([www.emhg.org](http://www.emhg.org)). A further 29 of the 150 potentially pathogenic variants were found in more than one family. These are presented in Table 1, along with the prevalence in the European non-Finnish cohort of the ExAC browser. The difference in prevalence between the UK MH cohort and the ExAC browser cohort was statistically significant for 25 of these 29 variants (Table 1). All of these variants were found in the heterozygous state except p.Arg3772Gln which we have previously reported in 3 of the 6 families listed in Table 1 27. In total, 546 of 722 families carry at least one pathogenic, likely pathogenic or potentially pathogenic *RYR1* variant

**Variants in the *CACNA1S* gene**

Two *CACNA1S* variants, p.Arg174Trp. and p.Arg1086His, have been functionally characterized 28, 29 and are recognized as pathogenic variants by the European MH Group (www.emhg.org). We have previously reported p.Arg174Trp 14 and p.Thr1009Lys 30, 24  in one and two families respectively. We now report an additional family with p.Arg174Trp. Of the total of 14 potentially pathogenic *CACNA1S* variants (Table 2) there were only two found in more than one family, p.Thr1009Lys and p.Arg1086Ser. For p.Thr1009Lys this prevalence compares with 3 of 33,279 samples of the ExAC European non-Finnish cohort indicating that the variant is over-represented in MH families (chi-sq 40.28, *P* < 1 x 10-8) and meets our criteria for classifying it as likely pathogenic.

The p.Arg1086Ser variant has previously been reported in association with MH 31 and involves substitution of the same amino acid as the functionally characterized p.Arg1086His variant. The p.Arg1086Ser variant was not found in the European non-Finnish ExAC cohort but our two families were both of South Asian origin. Comparison of the prevalence of this variant in our cohort with the ExAC South Asian cohort (3 out of 8,256 samples) did not reach our criteria for classifying this variant as likely pathogenic (chi-sq 8.315, *P* = 0.0039). In fact, several of our potentially pathogenic *CACNA1S* variants were found in patients with a non-white ethnic background. Both patients with the p.Arg174Trp variant were black/African/Caribbean, although this variant was not found in any of 5,188 samples in the ExAC African cohort. Three other variants (p.Met827Thr, p.Ala1271Thr, p.Leu1832ArgfsTer67) were each found in single patients of black/African/Caribbean ethnicity and based on prevalence data from the ExAC African cohort it seems unlikely that these variants are pathogenic (314 of 3836, 202 of 10192 and 195 of 10198 samples respectively). In addition to p.Arg1086Ser, three further variants were found only in patients of South Asian origin. Two of these, p.Pro758Leu and p.Leu885Pro were found in the same patient, while p.His992Asp was also present in a single patient. The prevalence for each of these variants in the ExAC South Asian cohort was < 1 in 1,000 and so these variants remain potentially pathogenic.

One of the *CACNA1S* variants meeting our criteria for being potentially pathogenic in MH, p.Arg900Ser, has previously been reported in association with hypokalaemic periodic paralysis 32. This and another *CACNA1S* variant, p.Gly1210Arg, were found in a patient who we have previously reported 33 with a history of hypokalaemic periodic paralysis and MH, and the *RYR1* c.7025A>G, p.Asn2342Ser variant. Four other families with potentially pathogenic *CACNA1S* variants also had a potentially pathogenic *RYR1* variant. There were 8 families with pathogenic or potentially pathogenic *CACNA1S* variants only.

**Variants in the *STAC3* gene**

We found the previously reported p.Trp284Ser variant in 3 families with one proband being homozygous for this variant. No novel potentially pathogenic variants were found in *STAC3*.

**Families where variants in the coding regions of *RYR1*, *CACNA1S* and *STAC3* were not found**

We found potentially pathogenic variants in 555 of 722 families. Of the remaining 167 families, *RYR1*, *CACNA1S* and *STAC3* were sequenced with NGS in 103 families, with the sequence of regions of low quality reads being confirmed by Sanger sequencing.

**Segregation analyses**

Segregation between genotype and IVCT phenotype was assessed in 328 families with an *RYR1* variant and 4 families with *CACNA1S* variants. The median (range) number of MH susceptible and MH normal members included per family was 2 (1 -16) and 3 (1 - 27) respectively. In families carrying a pathogenic *RYR1* variant there were 72 out of 280 families with at least one example of genotype-phenotype discordance (Table 3). In families carrying a likely pathogenic *RYR1* variant there were 14 out of 48 families with at least one example of genotype-phenotype discordance (Table 4).

**Families with more than one variant**

We have identified 27 of 293 families where sequencing of the entire coding regions of the three genes has been done in which more than one potentially pathogenic variant in *RYR1*, *CACNA1S* or *STAC3* has been identified. The number of families with 2, 3, or 4 such variants was 21, 5, and 1 respectively.

**Discussion**

In this paper we provide the best estimate to date of the prevalence and distribution of genetic variants in MH susceptible families in a principally European Caucasian population. *RYR1* variants were found in 546 of 722 independent families corresponding to an estimate of 76% (95% CI 72-79%). We have confirmed the extent of allelic heterogeneity within *RYR1* and demonstrated that the majority of *RYR1* variants in our population are private to individual families. However, just 28 variants are implicated in > 50% of our MH families, with one variant, p.Gly2434Arg, found in almost 16% of MH families. Interestingly, in 434 families we reported in 2006 we identified 52 *RYR1* variants of which ~ 50% were private to individual families 5. Other than our cohort, the largest evaluation of the prevalence of *RYR1* variants associated with MH susceptibility included 120 families from the United States 11 of which 62 (52%, 95% CI 43-61%) had *RYR1* variants. A total of 96 Australian patients have been included in two reports from the group of Gillies 8, 12 and 33 of these were found to carry *RYR1* variants (34%, 95% CI 25-44%). Estimates of the prevalence of *RYR1* variants in other populations included smaller numbers of patients: Japan, 33 out of 58 patients (57%, 95% CI 43-70%) 6; Italy, 31 out of 43 patients (72%, 95% CI 56-85%) 7; Canada, 31 out of 36 patients (86%, 95% CI 70-95%) 10; Sweden, 7 out of 14 patients (50%, 95% CI 23-77%) 9. *RYR1* prevalence estimates lower than ours are likely to be at least partially attributable to either incomplete screening of the *RYR1* gene or reliance on Sanger sequencing which is not as sensitive as NGS for variant detection 30. For the Canadian cohort, Kraeva and colleagues 10 selected MH susceptible patients with the clearest clinical episodes and strongest caffeine-halothane contracture test responses and this may explain their point estimate of 86% prevalence of *RYR1* variants, although their 95% CI fully encompasses our 95% CI.

The EMHG published its first guideline for classification of high-risk genetic variants in MH susceptibility in 2001 34 which was based on contemporary standards of molecular genetic diagnoses. Key to confirming pathogenicity of missense variants, the type of variant most frequently associated with MH susceptibility, was the demonstration of a functional effect of the variant consistent with the known pathophysiology of the condition. The technical difficulty and cost of the necessary experiments has limited the number of variants found in MH patients that have been functionally characterized 19.

Current generic guidelines 35 for the diagnostic classification of genetic variants incorporate 5 classes: benign, likely benign, variant of unknown significance, likely pathogenic and pathogenic: variants within the last two categories are usually considered suitable for prospective diagnostic testing. Within the current European MH Group guidelines 18, there are broadly two categories of functional tests: *ex vivo* experiments on cells cultured from MH susceptible patients and *in vitro* studies where the variant has been genetically engineered into homologous or heterologous expression systems. There is debate about the use of *ex vivo* cells for genetic variant characterization because of the potential for genetic background effects 18, 19 and it perhaps would be appropriate to classify variants characterized in this way as likely pathogenic.

The American College of Medical Genetics and Genomics and the Association for Molecular Pathology (ACMG/AMP) guideline 35 includes an algorithm to determine the classification of individual variants and we have attempted to apply this to the variants we have found. Using this algorithm, recurrent variants that have been functionally characterized using genetic engineering and homologous or heterologous expression systems are classified as pathogenic but none of our other variants could be classified beyond a variant of unknown significance despite many being found in multiple MH families but rarely in the control population.

Through comparing the prevalence of recurrent *RYR1* variants in our population with that of a relevant low-risk (for MH susceptibility) population presented within the ExAC browser dataset, we have provided compelling statistical evidence that a further 25 *RYR1* variants are likely to be pathogenic. We suggest that these are suitable to be used in prospective DNA diagnosis of MH susceptibility within the framework for diagnostic testing recommended by the European MH Group 18. This framework enables the presence of a likely pathogenic or pathogenic variant to be used to confirm high-risk status but requires the absence of a familial variant to be confirmed by IVCT in order for a sufficiently low-risk status to be assigned such that the patient may safely receive MH triggering anaesthetics. Addition of these 25 *RYR1* variants to the diagnostic panel would enable a further 97 UK MH families to benefit from prospective DNA diagnosis.

Pathogenic or potentially pathogenic *CACNA1S* variants were found in 13 (1.8%, 95% CI 1-3%) UK MH families but 5 of these families also carried a potentially pathogenic *RYR1* variant. Our previous review of *RYR1* variants 5 highlighted that the distribution of variants was spread widely across the gene, rather tan in three “hot-spots” previously described. We now report a similar situation in *CACNA1S* with variants that are at least potentially pathogenic occurring between amino acid positions 174 and 1696 (Table 2). Furthermore, the variants affect a variety of functional sites within the Cav1.1 protein  36. The p.Arg174 amino acid is one of the positively charged residues of the S4 segment of domain I: the S4 segments are thought to be the voltage sensors of the protein. Mutations of the arginine residues of the S4 segments of domains III (p.Arg900) 34, 37 and IV (p.Arg1239) 38, 39 cause hypokalaemic periodic paralysis while the p.Arg1242Gly variant (domain IV S4) is associated with normokalaemic periodic paralysis 40. The p.Asn909Ser found in our cohort also affects the S4 segment of domain III.

The amino acid p.Arg1086 is located in the cytoplasmic loop between domains III and IV and this loop has been shown to influence RyR1 channel gating 41. One of our new variants to be associated with MH susceptibility, p.Pro758Leu, is located in the domain I-II cytoplasmic loop in a region thought to be critical for excitation-contraction coupling. Three of our potentially pathogenic *CACNA1S* variants, p.Tyr617Ala, p.His992Asp and p.Thr1009Lys, may affect the Cav1.1 channel pore regions of domains II, III and III respectively. A potential mechanism for pathogenicity of our other *CACNA1S* variants is less clear.

Our single case of homozygous presentation of the p.Trp284Ser *STAC3* variant was in a patient from the Middle East. It is interesting that this variant is present in 0.12% of the African population, suggesting that it did not originate in the Native American population from which the congenital myopathy derived its name.

Of 722 families, we have excluded *RYR1*, *CACNA1S* and *STAC3* variants in 103 families using NGS. No variants in these genes have been found in a further 64 families but the genetic analyses of these families have not been so extensive as to conclude that variants in *RYR1*, *CACNA1S* and *STAC3* are not present. We can therefore provide a range of estimates for non-*RYR1/CACNA1S/STAC3* MH susceptibility of between 14% (95% CI 11.5-17%) and 23% (95% CI 20-26%). As with other groups 42 we have used NGS to search for variants in other genes  30 but the analytical approach to distinguish potentially pathogenic from benign variants is challenging 2.

We first reported discordance within a family between a functionally relevant *RYR1* variant and the IVCT phenotype 20 years ago 43. Similar findings have been reported across European laboratories 20. Since the introduction of predictive testing for familial variants, high risk status indicated by the presence of a familial variant has not required to be confirmed with a subsequent IVCT, which is not the case for low risk status in the absence of a familial variant. There has therefore been an inevitable bias in the type of discordance recorded over the past 15 years, with only a susceptible phenotype in the absence of a familial variant detected. The occurrence of discordance appears to be distributed equally among the various *RYR1* variants, with the number of discordant cases reflecting the number of families harbouring the variant where segregation analyses have been done. The possible exception to this is *RYR1* p.Arg2435His where we found no cases of genotype-phenotype discordance in 10 families where segregation analyses had been conducted. It is interesting to note that this variant was found to be associated with one of the “strongest” IVCT phenotypes 44. In that paper we proposed a threshold genetic model for MH susceptibility to explain genotype-phenotype discordance. If this is the case, the extent of genotype-phenotype discordance that we now present could suggest that very few *RYR1* variants are sufficiently penetrant to consistently cause MH susceptibility in the absence of other genetic risk factors. Such a situation would be consistent with the high combined prevalence of known pathogenic *RYR1* variants 2.

An alternative explanation for genotype-phenotype discordance is errors in either genotyping or phenotyping. The genotypes of all our discordant cases involving pathogenic variants have been confirmed under strict diagnostic laboratory quality control procedures. The IVCT responses of discordant cases have been evaluated using a predictive model 25 to minimize the likelihood of misdiagnosis. We also routinely send a sample of the muscle biopsy for histological and histochemical analyses to exclude muscle pathology as a cause of a false positive IVCT 45-47 . The number of false positive IVCT results in a cohort of 202 subjects at low risk for MH susceptibility was reported by the European MH Group to be 13 (6.43%) 48. Out of 656 patients tested negative for a familial mutation, we found 79 (12.04%) to have a positive IVCT phenotype (Tables 3 and 4). The difference in these proportions is 5.61% (95% CI 0.78-9.39%, *P* = 0.024), which further argues against phenotyping error as an explanation for genotype-phenotype discordance. Our hypothesis that genotype-phenotype discordance is a result of the presence of more than one genetic risk factor for MH susceptibility is supported by our finding of more than one potentially pathogenic variant in 9.2% (95% CI 6.2-13.1%) of the 293 families in which *RYR1*, *CACNA1S* and *STAC3* had been fully sequenced.

In conclusion, we have described the most comprehensive genetic analysis of MH susceptibility to date. All of the families included have a relevant anaesthetic history and the diagnosis has been confirmed by internationally accepted diagnostic tests. Our data confirm the importance of variants in *RYR1* and the high proportion of these that are private to single families. We propose that 25 recurrent *RYR1* variants can be used for prospective genetic diagnosis of high risk status for MH susceptibility. The prevalence of potentially pathogenic variants in *CACNA1S* is slightly higher than previous estimates and our data suggest that their role in non-white populations may be even more important. We present further evidence for a role of genes other than *RYR1*, *CACNA1S* and *STAC3* and for combinations of genetic variants playing a role in at least a significant minority of MH families.

**References**

1. Hopkins PM. Malignant hyperthermia – pharmacology of triggering. *Br J Anaesth* 2011; **107**:48-56
2. Riazi S, Kraeva N, Hopkins PM.Malignant hyperthermia in the post-genomics era: new perspectives on an old concept. *Anesthesiology* 2018;**128**:168-80
3. MacLennan DH, Duff C, Zorzato F, et al. Ryanodine receptor gene is a candidate for predisposition to malignant hyperthermia. *Nature* 1990;**343**:559-61
4. McCarthy TV, Healy JM, Heffron JJ, et al. Localization of the malignant hyperthermia susceptibility locus to human chromosome 19q12-13.2. *Nature* 1990;**342**:562-4
5. Robinson RL, Carpenter D, Shaw M-A, Halsall PJ, Hopkins PM. Mutations in *ryr1* in malignant hyperthermia and central core disease. *Hum Mutat* 2006; **27**: 977-89
6. Ibarra M CA, Wu S, Murayama K, Minami N, Ichihara Y, Kikuchi H, Noguchi S, Hayashi YK, Ochiai R, Nishino I. Malignant hyperthermia in Japan: mutation screening of the entire ryanodine receptor type 1 gene coding region by direct sequencing. *Anesthesiology* 2006;**104**:1146-54.
7. Galli L, Orrico A, Lorenzini S, et al. Frequency and localization of mutations in the 106 exons of the RYR1 gene in 50 individuals with malignant hyperthermia. *Hum Mutat* 2006;**27**:830
8. Gillies R, Bjorksten A, Davis M, Du Sart D. Identification of genetic mutations in Australian malignant hyperthermia families using sequencing of RYR1 hotspots. *Anaesth Intensive Care* 2008; **36**:391-403
9. Broman M, Gehrig A, Islander G, et al. Mutation screening of the RYR1-cDNA from peripheral B-lymphocytes in 15 Swedish malignant hyperthermia index cases. *Br J Anaesth* 2009;102:642-9.
10. Kraeva N, Riazi, S, Loke J, et al. Ryanodine receptor type 1 gene mutations found in the Canadian malignant hyperthermia population. *Can J Anesth* 2011; **58**:504–13
11. Brandom BW, Bina S, Wong CA, et al. Ryanodine receptor type 1 gene variants in the malignant hyperthermia-susceptible population of the United States. *Anesth Analg* 2013; **116**: 1078–86
12. Gillies RL, Bjorksten AR, Du Sart D, Hockey BM. Analysis of the entire ryanodine receptor type 1 and alpha 1 subunit of the dihydropyridine receptor (CACNA1S) coding regions for variants associated with malignant hyperthermia in Australian families. *Anaesth Intensive Care* 2015; **43**: 157-66
13. Monnier N, Procaccio V, Stieglitz P, Lunardi J. Malignant-hyperthermia susceptibility is associated with a mutation of the alpha 1-subunit of the human dihydropyridine-sensitive L-type voltage-dependent calcium-channel receptor in skeletal muscle. *Am J Hum Genet* 1997; **60**: 1316-25
14. Carpenter D, Ringrose C, Leo V, et al.The role of *CACNA1S* in predisposition to malignant hyperthermia. *BMC Med Genet* 2009; **10**:104
15. Polster A, Perni S, Bichraoui H, Beam KG. Stac adaptor proteins regulate trafficking and function of muscle and neuronal L-type Ca2+ channels. *Proc Natl Acad Sci USA* 2015;**112**:602-6
16. Polster A, Nelson BR, Olson EN, Beam KG. Stac3 has a direct role in skeletal muscle-type excitation-contraction coupling that is disrupted by a myopathy-causing mutation. *Proc Natl Acad Sci USA* 2016;**113**:10986-91.
17. Horstick EJ, Linsley JW, Dowling JJ, et al. Stac3 is a component of the excitation-contraction coupling machinery and mutated in Native American myopathy. *Nat Commun* 2013;**4**:1952
18. Hopkins PM, Rüffert H, Snoeck MM, et al. The European Malignant Hyperthermia Group guidelines for the investigation of malignant hyperthermia susceptibility. *Br J Anaesth* 2015; **115**: 531-9
19. Merritt A, Booms P, Shaw M-A, et al. Assessing the pathogenicity of *RYR1* variants in malignant hyperthermia. *Br J Anaesth* 2017*;* **118**:533-43
20. Robinson RL, Anetseder MJ, Brancadoro V, et al. Recent advances in the diagnosis of malignant hyperthermia susceptibility: how confident can we be of genetic testing? *Eur J Hum Genet* 2003;**11**:342-8
21. European MH Group. A protocol for the investigation of malignant hyperpyrexia (MH) susceptibility. *Br J Anaesth* 1984; **56**: 1267-9
22. European MH Group. Laboratory diagnosis of malignant hyperpyrexia susceptibility (MHS). *Br J Anaesth* 1985; **57**:1038
23. Gillard EF, Otsu K, Fujii J, et al. A substitution of cysteine for arginine 614 in the ryanodine receptor is potentially causative of human malignant hyperthermia. *Genomics* 1991;**11**:751-5
24. Fiszer D, Shaw M-A, Fisher NA, et al. Next generation sequencing of *RYR1* and *CACNA1S* in malignant hyperthermia and exertional heat illness. *Anesthesiology* 2015: **122**;1033-46
25. Hopkins PM, Halsall PJ, Ellis FR, Stewart AD. An analysis of the predictive probability of the *in vitro* contracture test for determining malignant hyperthermia susceptibility. *Anesth Analg* 1997; **84**: 648-56
26. Kircher M, Witten DM, Jain P, O'Roak BJ, Cooper GM, Shendure J. A general framework for estimating the relative pathogenicity of human genetic variants. *Nat Genet* 2014;**46**:310-5
27. Carpenter D, Ismail A, Robinson RL, et al. A *RYR1* mutation associated with recessive congenital myopathy and dominant malignant hyperthermia in Asian families. *Muscle Nerve* 2009; **40**: 663-9
28. Weiss RG, O’Connell KM, Flucher BE, Allen PD, Grabner M, Dirksen RT.  Functional analysis of the R1086H malignant hyperthermia mutation in the DHPR reveals an unexpected influence of the III-IV loop on skeletal muscle EC coupling. *Am J Physiol Cell Physiol* 2004; **287**: C1094-102
29. Eltit JM, Bannister RA, Moua O, et al. Malignant hyperthermia susceptibility arising from altered resting coupling between the skeletal muscle L-type Ca2+ channel and the type 1 ryanodine receptor. *Proc Natl Acad Sci USA* 2012; **109**: 7923-8
30. Kim J, Jarvik GP, Browning BL, et al. Exome sequencing reveals novel rare variants in ryanodine receptor and calcium channel genes in malignant hyperthermia families. *Anesthesiology* 2013; **119**: 1054-65
31. Toppin PJ, Chandy TT, Ghanekar A, Kraeva N, Beattie WS, Riazi S. A report of fulminant malignant hyperthermia in a patient with a novel mutation of the CACNA1S gene. *Can J Anaesth* 2010;**57**:689-93
32. Matthews E, Labrum R, Sweeney MG, et al. Voltage sensor charge loss accounts for most cases of hypokalemic periodic paralysis. *Neurology* 2009;**72**:1544-7
33. Marchant CL, Ellis FR, Halsall PJ, Hopkins PM, Robinson RL. Mutation analysis of two patients with hypokalemic periodic paralysis and suspected malignant hyperthermia. *Muscle Nerve* 2004;**30**:114-7
34. Urwyler A, Deufel T, McCarthy T, West S. Guidelines for the molecular detection of susceptibility to malignant hyperthermia. *Br J Anaesth* 2001; **86**: 283-7
35. Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet Med* 2015;**17**:405-24
36. Wu J, Yan Z, Li Z, et al. Structure of the voltage-gated calcium channel Cav1.1 at 3.6 Å resolution. *Nature* 2016**; 537**: 191–6
37. Hirano M, Kokunai Y, Nagai A, et al. A novel mutation in the calcium channel gene in a family with hypokalemic periodic paralysis. *J Neurol Sci* 2011;**309**:9-11
38. Ptácek LJ, Tawil R, Griggs RC, et al. Dihydropyridine receptor mutations cause hypokalemic periodic paralysis. *Cell* 1994;**77**:863-8
39. Elbaz A, Vale-Santos J, Jurkat-Rott K, et al. Hypokalemic periodic paralysis and the dihydropyridine receptor (CACNL1A3): genotype/phenotype correlations for two predominant mutations and evidence for the absence of a founder effect in 16 caucasian families. *Am J Hum Genet* 1995;**56**:374-80
40. Fan C, Lehmann-Horn F, Weber MA, et al. Transient compartment-like syndrome and normokalaemic periodic paralysis due to a Ca(v)1.1 mutation. *Brain* 2013;**136**:3775-86
41. Bannister RA, Grabner M, Beam KG. The alpha(1S) III-IV loop influences 1,4-dihydropyridine receptor gating but is not directly involved in excitation-contraction coupling interactions with the type 1 ryanodine receptor. *J Biol Chem* 2008;**283**:23217-23
42. Schiemann AH, Dürholt EM, Pollock N, Stowell KM. Sequence capture and massively parallel sequencing to detect mutations associated with malignant hyperthermia. *Br J Anaesth* 2013;**110**:122-7
43. Adeokun AM, West SP, Ellis FR, et al. The G1021A substitution in the RYR1 gene does not always cosegregate with malignant hyperthermia susceptibility in a British pedigree*. Am J Hum Genet* 1997; **60**: 833-41
44. Carpenter D, Robinson RL, Quinnell RJ, et al. Genetic variation in RYR1 and malignant hyperthermia phenotypes. *Br J Anaesth* 2009; **103**: 538-48
45. Hopkins PM, Ellis FR, Halsall PJ. Comparison of in vitro contracture testing with halothane, caffeine and ryanodine in patients with malignant hyperthermia and other neuromuscular disorders. *Br J Anaesth* 1993;**70**:397-401
46. Lehmann-Horn F, Iaizzo PA. Are myotonias and periodic paralyses associated with susceptibility to malignant hyperthermia? *Br J Anaesth* 1990; **65**: 692-7
47. Heiman-Patterson T, Rosenberg H, Fletcher JE, Tahmoush AJ. Halothane-caffeine contracture testing in neuromuscular diseases. *Muscle Nerve* 1988; **11**: 453-7
48. Ording H, Brancadoro V, Cozzolino S, et al. In vitro contracture test for diagnosis of malignant hyperthermia following the protocol of the European MH Group: results of testing patients surviving fulminant MH and unrelated low-risk subjects. *Acta Anaesthesiol Scand* 1997;**41**:955-66

**Table 1. Non-functionally characterized *RYR1* variants present in more than one MH family**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Nucleotide Change** | **Amino acid change** | **No of families** | **ExAC MAF\*** | **Χ2** | ***P* value** |
| c.479A>G | p.Glu160Gly | 2 | 0/66620 | 92 | < 1x 10-7 |
| c.529C>T | p.Arg177Cys | 10 | 0/64006 | 443 | < 1x 10-7 |
| c.641C>T | p.Thr214Met | 4 | 11/66646 | 43.5 | < 1x 10-7 |
| c.1202G>T | p.Arg401His | 2 | 0/66660 | 92 | < 1x 10-7 |
| c.1598G>A | p.Arg533His | 2 | 3/66740 | 34.6 | < 1x 10-7 |
| c.1615T>G | p.Phe539Val | 2 | 0/66740 | 92 | < 1x 10-7 |
| c.3166G>C | p.Asp1056His | 2 | 0/7566 | 10.48 | 0.0012 |
| c.4763C>T | p.Pro1588Leu | 2 | 1/9516 | 7.51 | 0.0061 |
| c.5024T>C | p. Leu1675Pro | 3 | 0/65086 | 135 | < 1x 10-7 |
| c.5183C>T | p. Ser1728Phe | 8 | 0/65086 | 361 | < 1x 10-7 |
| c.6612C>G | p.His2204Gln | 5 | 0/66430 | 230 | < 1x 10-7 |
| c.6961A>G | p.Ile 2321Val | 3 | 41/66520 | 4.66 | 0.031 |
| c.7084G>A | p.Glu2362Lys | 2 | 0/62220 | 86 | < 1x 10-7 |
| c.7089C>G | p.Cys 2363Trp | 2 | 0/61940 | 86 | < 1x 10-7 |
| c.7090T>G | p.Phe2364Val | 2 | 0/61754 | 85 | < 1x 10-7 |
| c.7291G>T | p. Asp2431Tyr | 3 | 0/66508 | 138 | < 1x 10-7 |
| c.7879G>A | p.Val2627Met | 5 | 0/66484 | 230 | < 1x 10-7 |
| c.8026C>T | p. Arg2676Trp | 3 | 1/66588 | 102 | < 1x 10-7 |
| c.9152G>A | p.Arg3051His | 2 | 24/66740 | 3.9 | 0.048 |
| c.10252A>G | p.Asn3418Asp | 2 | 0/31266 | 43 | < 1x 10-7 |
| c.11708G>A | p.Arg3903Gln | 2 | 2/66740 | 44 | < 1x 10-7 |
| c.11315G>A | p. Arg3772Gln | 7 (2 HOM) | 0/14896 (South Asian) | 83 | < 1x 10-7 |
| c.11958C>G | p.Asp3986Glu | 6 | 0/66312 | 276 | < 1x 10-7 |
| c.12149C>A | p.Ser4050Tyr | 2 | 0/66732 | 92 | < 1x 10-7 |
| c.12700G>T | p.Val4234Leu | 5 | 0/15016 | 52 | < 1x 10-7 |
| c.14210G>A | p.Arg4737Gln | 7 | 1/66574 | 280 | < 1x 10-7 |
| c.14471T>C | p.Leu4824Pro | 3 | 0/66704 | 139 | < 1x 10-7 |
| c.14678G>A | p.Arg4893Gln | 3 | 0/66322 | 138 | < 1x 10-7 |
| c.14918C>T | p.Pro4973Leu | 3 | 3/66446 | 66 | < 1x 10-7 |

ExAC: ExAC browser (<http://exac.broadinstitute.org)>. MAF: minor allele frequency. \*- MAF for the European non-Finnish cohort unless otherwise stated

**Table 2. *CACNA1S* variants in the UK malignant hyperthermia cohort that are rare in the European non-Finnish cohort of the ExAC browser**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Nucleotide change** | **Amino acid change** | **Functionally characterized** | **No. of families** | **ExAC MAF\*** |
| c.520C>T | p.Arg174Trp | Yes | 2 | 1/66510(0/10376 African) |
| c.1426A>C | p.Thr476Pro | No | 1 | 0/66738 |
| c.1849A>G | p.Thr617Ala | No | 1 | 0/66738 |
| c.2273C>T | p.Pro758Leu | No | 1 | 1/66696(0/16512 South Asian) |
| c.2440G>A | p.Ala814Thr | No | 1 | 89/35776 |
| c.2480T>C | p.Met827Thr | No | 1 | 4/46716(314/7672 African) |
| c.2654T>C | p.Leu885Pro | No | 1 | 0/65598 (0/16054 South Asian) |
| c.2700G>T | p.Arg900Ser | No | 1 | 0/66652 |
| c.2726A>G | p.Asn909Ser | No | 1 | 2/66708 |
| c.2974C>G | p.His992Asp | No | 1 | 0/66126 (6/16362 South Asian) |
| c.3026C>A | p.Thr1009Lys | No | 2 | 3/66558 |
| c.3332C>A | p.Arg1086Ser | No | 2 | 0/66740(3/16512 South Asian) |
| c.3628G>A | p.Gly1210Arg | No | 1 | 56/61616 |
| c.3811G>A | p.Ala1271Thr | No | 1 | 6/66586(202/10384 African) |
| c.5087C>T | p.Thr1696Met | No | 1 | 2/65668 |
| 1:201009083 AGTAGCTCT/A | p.Leu1832ArgfsTer67 | No | 1 | 6/66710(195/10396 African) |

ExAC: ExAC browser (<http://exac.broadinstitute.org)>. MAF: minor allele frequency. \*- MAF for the European non-Finnish cohort unless otherwise stated

**Table 3. Segregation analyses of *RYR1* variants reported as pathogenic by the European Malignant Hyperthermia Group (www.emhg.org)**

|  |  |  |  |
| --- | --- | --- | --- |
| **Nucleotide change** | **Amino acid change** | **No. of UK families** | **No. of discordant UK families** |
|  |  | **total** | **segregation** | **G+/P-** | **G-/P+** | **Both** |
| c.103T>C | p.Cys35Arg | 0 |  |  |  |  |
| c.487C>T | p.Arg163Cys | 21 | 14 | 1 | 2 |  |
| c.488G>T | p.Arg163Leu | 2 | 1 |  |  |  |
| c.742G>A | p.Gly248Arg | 5 | 4 | 1 | 1a |  |
| c.742G>C | p.Gly248Arg | 3 | 2 |  |  |  |
| c.1021G>A | p.Gly341Arg | 31 | 27 | 1 | 6b | 2 |
| c.1201C>T | p.Arg401Cys | 2 |  |  |  |  |
| c.1209C>G | p.Ile403Met | 0 |  |  |  |  |
| c.1565A>C | p.Tyr522Ser | 0 |  |  |  |  |
| c.1589G>A | p.Arg530His | 1 |  |  |  |  |
| c.1654C>T | p.Arg552Trp | 4 | 4 |  | 1 |  |
| c.1840C>T | p.Arg614Cys | 14 | 7 |  | 1 |  |
| c.1841G>T | p.Arg614Leu | 1 |  |  |  |  |
| c.6487C>T | p.Arg2163Cys | 2 | 1 | 1 |  |  |
| c.6488G>A | p.Arg2163His | 9 | 8 | 2 | 3 |  |
| c.6502G>A | p.Val2168Met | 8 | 6 |  | 3 b |  |
| c.6617C>G | p.Thr2206Arg | 1 |  |  |  |  |
| c.6617C>T | p.Thr2206Met | 28 | 24 | 3 | 4 | 1 |
| c.7007G>A | p.Arg2336His | 9 | 7 |  | 1 b | 1 a |
| c.7042GAG>del | p.Gln2348del | 0 |  |  |  |  |
| c.7048G>A | p.Ala2350Thr | 7 | 7 |  | 2 |  |
| c.7063C>T | p.Arg2355Trp | 8 | 6 |  | 1 |  |
| c.7124G>C | p.Gly2375Ala | 0 |  |  |  |  |
| c.7282G>A | p.Ala2428Thr | 1 |  |  |  |  |
| c.7300G>A | p.Gly2434Arg | 118 | 96 | 6 | 13 b c | 2 |
| c.7304G>A | p.Arg2435His | 11 | 10 |  |  |  |
| c.7354C>T | p.Arg2452Trp | 2 | 2 |  |  |  |
| c.7360C>T | p.Arg2454Cys | 0 |  |  |  |  |
| c.7361G>A | p.Arg2454His | 14 | 11 | 1 | 2 b |  |
| c.7372C>T | p.Arg2458Cys | 0 |  |  |  |  |
| c.7373G>A | p.Arg2458His | 15 | 12 |  | 2 b |  |
| c.7522C>T | p.Arg2508Cys | 1 |  |  |  |  |
| c.7523G>A | p.Arg2508His | 4 | 2 |  | 1 |  |
| c.9310G>A | p.Glu3104Lys | 5 | 3 |  |  |  |
| c.11969G>T | p.Gly3990Val | 11 | 7 |  | 1 |  |
| c.14387A>G | p.Tyr4796Cys | 0 |  |  |  |  |
| c.14477C>T | p.Thr4826Ile | 10 | 10 |  | 3 |  |
| c.14497C>T | p.His4833Tyr | 0 |  |  |  |  |
| c.14512C>G | p.Leu4838Val | 1 | 1 |  |  |  |
| c.14545G>A | p.Val4849Ile | 8 | 8 |  | 3 b |  |
| c.14582G>A | p.Arg4861His | 0 |  |  |  |  |
| c.14693T>C | p.Ile4898Thr | 0 |  |  |  |  |

G+/P-: +ve for genotype and -ve for phenotype

G-/P+:–ve for genotype and +ve for phenotype

a: 1 family has 3 individuals –ve for genotype and +ve for phenotype

b: 1 family has 2 individuals –ve for genotype and +ve for phenotype

c: 1 family has 5 individuals –ve for genotype and +ve for phenotype

**Table 4. Segregation of recurrent *RYR1* variants in the UK malignant hyperthermia cohort**

|  |  |  |  |
| --- | --- | --- | --- |
| **Nucleotide change** | **Amino acid change** | **No. of UK families** | **No. of discordant UK families** |
|  |  | **total** | **segregation** | **G+/P-** | **G-/P+** | **Both** |
| c.479A>G | p.Glu160Gly | 2 | 0 |  |  |  |
| c.529C>T | p.Arg177Cys | 10 | 8 | 1 | 2 |  |
| c.641C>T | p.Thr214Met | 4 | 3 |  |  |  |
| c.1202G>T | p.Arg401His | 2 |  |  |  |  |
| c.1598G>A | p.Arg533His | 2 |  |  |  |  |
| c.1615T>G | p.Phe539Val | 2 |  |  |  |  |
| c.3166G>C | p.Asp1056His | 2 | 1 |  |  |  |
| c.4763C>T | p.Pro1588Leu | 2 |  |  |  |  |
| c.5024T>C | p.Leu1675Pro | 3 | 0 |  |  |  |
| c.5183C>T | p.Ser1728Phe | 8 | 6 |  |  | 1 |
| c.6612C>G | p.His2204Gln | 5 | 1 |  |  |  |
| c.6961A>G | p.Ile2321Val | 3 | 1 | 1a |  |  |
| c.7025A>G | p.Asn2342Ser | 8 | 1 |  |  |  |
| c.7084G>A | p.Glu2362Lys | 2 | 1 |  |  |  |
| c.7089C>G | p.Cys2363Trp | 2 | 1 |  | 1 |  |
| c.7090T>G | p.Phe2364Val | 2 |  |  |  |  |
| c.7291G>T | p.Asp2431Tyr | 3 | 3 |  | 1 |  |
| c.7879G>A | p.Val2627Met | 5 | 2 |  | 1 | 1 |
| c.8026C>T | p.Arg2676Trp | 3 | 3 |  |  | 1 |
| c.9152G>A | p.Arg3051His | 2 |  |  |  |  |
| c.10252A>G | p.Asn3418Asp | 2 | 0 |  |  |  |
| c.11708G>A | p.Arg3903Gln | 2 |  |  |  |  |
| c.11315G>A | p.Arg3772Gln | 7 (2 HOM) | 2 | 1b |  |  |
| c.11958C>G | p.Asp3986Glu | 6 | 2 |  |  |  |
| c.12149C>A | p.Ser4050Tyr | 2 | 2 |  |  |  |
| c.12700G>T | p.Val4234Leu | 5 | 1 |  |  |  |
| c.14210G>A | p.Arg4737Gln | 7 | 7 | 1 b | 2 |  |
| c.14471T>C | p.Leu4824Pro | 3 |  |  |  |  |
| c.14678G>A | p.Arg4893Gln | 3 | 1 |  |  |  |
| c.14918C>T | p.Pro4973Leu | 3 | 2 |  |  |  |

G+/P-: +ve for genotype and -ve for phenotype

G-/P+:–ve for genotype and +ve for phenotype

a: 1 family has 3 individuals –ve for genotype and +ve for phenotype

b: 1 family has 2 individuals –ve for genotype and +ve for phenotype